Clinical trials: Vaccination
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Human Papilloma Virus
Text Reminders to Immunize in a Managed Care Organization
The purpose of the study is to evaluate the effectiveness of a managed care-based HPV vaccination reminder/recall system using a randomized controlled trial (RCT) across diverse practices and patient populations.
- Trial name
- TRIO (NCT01806714)
- Testing
- Text-based reminder for recommended HPV vaccine or WCC, Non-specific text-based reminder (general health tip)
- Where
- United States
- Volunteers
- 3,812 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Japanese Encephalitis
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440
- Trial name
- NCT00596271
- Testing
- IC51, HAVRIX
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Alzheimer Disease
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00479557
- Testing
- ACC-001 + QS-21, ACC-001, QS-21
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Educational Activities
Getting Asian Americans INFORMED to Facilitate COVID-19 Testing and Vaccination
This study develops and evaluates the "INdividual and Family-Oriented Responsive Messaging EDucation" (INFORMED) intervention in increasing knowledge about COVID-19 testing and decreasing decisional conflicts of getting tested…
- Trial name
- INFORMED (NCT04893265)
- Testing
- Text Messaging Only, INFORMED
- Where
- 3 sites in United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Influenza, Vaccination
Lottery Incentive Nudges to Increase Influenza Vaccinations
In the current study, the study team will explore whether small incentives are effective at promoting flu vaccine uptake. The study is designed to compare the relative efficacy of incentives of equal perceived expected value (EV)…
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT05012163
- Testing
- Reminder, Financial incentive, Lottery
- Where
- United States
- Volunteers
- 57,581 people
- Sponsor
- National Bureau of Economic Research, Inc.
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Smallpox
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
Imvamune (licensed name of MVA being developed as a smallpox vaccine) has been tested in over 2,000 individuals and is on path for licensure.
- Trial name
- NCT01827371
- Testing
- MVA Smallpox Vaccine
- Where
- 6 sites in United States
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine, HIV-1-infection
Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART
This is a double blind, randomized, placebo-controlled, parallel design study in which 18 in participants with HIV (PWH) on suppressive antiretroviral therapy will be randomly assigned to receive vaccination with C62 followed by…
- Trial name
- CM HIV-CORE008 (NCT05604209)
- Testing
- ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Respiratory Disorders
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
The purpose of this long-term follow-up of a Phase I study is to evaluate the kinetics of the antibody response to NTHi-Mcat antigens and long-term safety, in subjects aged between 50-71 years at the time of enrolment in the…
- Trial name
- NCT03201211
- Testing
- Blood sampling, GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2., GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.
- Where
- 3 sites in Belgium
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma, Skin Cancer
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Background: gp100 is a protein that is often found in melanoma tumors. An experimental procedure developed for treating patients with melanoma uses anti-gp100 cells designed to destroy their tumors.
- Trial name
- NCT00610311
- Testing
- cyclophosphamide, fludarabine phosphate, Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes, Gestational
The Project Wellness Pilot Feasibility Randomized Controlled Trial
This pilot feasibility randomized controlled trial will be conducted among women at risk for or diagnosed with gestational diabetes (GDM) at the University of Tennessee Medical Center Knoxville (UTMC).
- Trial name
- NCT04209348
- Testing
- Physical Activity Intervention, Wellness Education
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Tennessee, Knoxville
Rotavirus
Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids administered with or without the GSK Biologicals' liquid Rotarix…
- Trial name
- NCT02907216
- Testing
- Squarekids, Rotarix
- Where
- 11 sites in Japan
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer, Colon Cancer
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging.
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT01339000
- Testing
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Meningitis, Meningococcal
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
- Trial name
- NCT00474526
- Testing
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib
- Where
- 63 sites in United States, Argentina and 1 more
- Volunteers
- 4,545 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01302860
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations.
- Trial name
- NCT05533918
- Testing
- Text-Messaging (TM), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 31,439 people
- Sponsor
- University of Utah
Influenza, Influenza Immunisation
Flublok or Fluzone With Advax-CpG55.2 or AF03
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03945825
- Testing
- AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 8 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine.
- Trial name
- NCT03294135
- Testing
- Encepur Adults
- Where
- Czechia
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline